Article

Antimicrobial activity of doripenem against Gram-negative pathogens: Results from INVITA-A-DORI Brazilian Study

Escola Paulista de Medicina-Universidade Federal de São Paulo, Rua Leandro Dupret 188, Sao Paulo, SP, Brazil.
The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases (Impact Factor: 1.3). 12/2011; 15(6):513-20. DOI: 10.1016/S1413-8670(11)70244-6
Source: PubMed

ABSTRACT

In vitro activity of doripenem and comparator antimicrobial agents was evaluated against Gram-negative bacilli recently isolated from Brazilian private hospitals that were enrolled in the INVITA-A-DORI Brazilian Study. A total of 805 unique Gram-negative bacilli were collected from patients hospitalized at 18 medical centers between May/08 and March/09. Each hospital was asked to submit 50 single Gram-negative bacilli isolated from blood, lower respiratory tract or intraabdominal secretions. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using Clinical Laboratory Standards Institute (CLSI) microdilution method at a central laboratory. CLSI M100-S21 (2011) or US-FDA package insert criteria (tigecycline) was used for interpretation of the antimicrobial susceptibility results. Doripenem was as active as meropenem and more active than imipenem against E. coli and K. pneumoniae isolates. A total of 50.0% of Enterobacter spp. isolates were resistant to ceftazidime but 85.7% of them were inhibited at doripenem MICs < 1 µg/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MIC50/90, < 0.5/1 µg/mL) and P. aeruginosa (MIC50/90, 1/2 µg/mL). Although high rates of imipenem (53.1%) and meropenem (44.5%) resistance were detected among P. aeruginosa, doripenem showed MIC50 of 16 µg/mL against imipenem-resistant P. aeruginosa and inhibited a greater number of imipenem-resistant P. aeruginosa (10.5%) at MIC values of < 4 µg/mL than did meropenem (0.0%). In this study, doripenem showed similar in vitro activity to that of meropenem and retained some activity against imipenem-resistant P. aeruginosa isolated from Brazilian medical centers.

Download full-text

Full-text

Available from: Raquel Girardello, Sep 24, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of this study was to evaluate the in vitro activity of doripenem compared to meropemen against local isolates of Pseudomonas aeruginosa (P. aeruginosa).Materials and methodsAt the San José Hospital in Bogotá-Colombia, a 300-bed teaching hospital, 83 nonduplicate isolates of P. aeruginosa were collected between 2009 and 2011. Meropenem and Doripenem Minimum Inhibitory Concentration (MIC) were determined by the E test method. The 2012 Clinical and Laboratory Standards Institute breakpoints for carbapenems were applied.ResultsThe global susceptibility of P. aeruginosa isolates to meropemen was 69% and to doripenem was 75%, being the CIM 50 and 90 (ug/mL) of 0.75 and 28.8 for meropenem and of 0.64 and 15.2 for doripenem.Conclusions The MIC of doripenem was lower than the corresponding MIC of meropenem. It is required to carry out local studies of this type in order to make adjustments to the institutional antibiotics protocol.
    Preview · Article · Dec 2012 · Infectio
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The aim of this study was to evaluate the in vitro activity of doripenem compared to meropemen against local isolates of Pseudomonas aeruginosa (P. aeruginosa). Materials and methods: At the San José Hospital in Bogotá-Colombia, a 300-bed teaching hospital, 83 nonduplicate isolates of P. aeruginosa were collected between 2009 and 2011. Meropenem and Doripenem Minimum Inhibitory Concentration (MIC) were determined by the E test method. The 2012 Clinical and Laboratory Standards Institute breakpoints for carbapenems were applied. Results: The global susceptibility of P. aeruginosa isolates to meropemen was 69% and to doripenem was 75%, being the CIM 50 and 90 (ug/mL) of 0.75 and 28.8 for meropenem and of 0.64 and 15.2 for doripenem. Conclusions: The MIC of doripenem was lower than the corresponding MIC of meropenem. It is required to carry out local studies of this type in order to make adjustments to the institutional antibiotics protocol.
    Preview · Article · Dec 2012 · Infectio
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Acinetobacter are among the most common bacteria isolated in hospital infections, especially in developing countries. Multi-drug, extended-drug or pan-drug resistance makes its treatment a real medical challenge. In the present review, the authors describe clinical and experimental data in order to present different current and potential future strategies to treat infections caused by multi-drug resistant Acinetobacter. The therapeutic options for carbapenems-resistant Acinetobacter are scarce, and the current options have poor pharmacokinetics aspects and several side effects. The combined therapy has been an alternative for multi-drug resistant Acinetobacter. However, this issue is always controversial. In some studies the combined therapy has showed superiority for some strains of Acinetobacter in animal models and in vitro studies. Studies with humans are scarce and poor quality to suggest the best approach for the treatment of infections caused by Acinetobacter baumannii multidrug resistant.
    Full-text · Article · Jul 2015 · Journal of Medical Microbiology
Show more